Electrospun solid dispersions of maraviroc for rapid intravaginal preexposure prophylaxis of HIV

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4855-4865

  Ball, Cameron ^a   Woodrow, Kim A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS USED INTRAVAGINALLY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOHEXANE DERIVATIVE; EXCIPIENT; MACROGOL DERIVATIVE; MARAVIROC; NANOFIBER; POLYSORBATE; POVIDONE; SUSPENSION; TOPICAL ANTIINFECTIVE AGENT; TRIAZOLE DERIVATIVE; WETTING AGENT;

CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; ELECTROCHEMICAL ANALYSIS; FEMALE; HIV INFECTIONS; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; KINETICS; PHARMACOLOGY; SUSPENSION; ULTRASTRUCTURE; WETTABILITY;

ADMINISTRATION, INTRAVAGINAL; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; CELL LINE; CELL SURVIVAL; CYCLOHEXANES; ELECTROCHEMICAL TECHNIQUES; EXCIPIENTS; FEMALE; HIV INFECTIONS; HUMANS; KINETICS; NANOFIBERS; POLYETHYLENE GLYCOLS; POLYSORBATES; POVIDONE; SUSPENSIONS; TRIAZOLES; VAGINAL CREAMS, FOAMS, AND JELLIES; WETTABILITY; WETTING AGENTS;

EID: 84905396254     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02564-14     Document Type: Article

References (41)

1. Abdool Karim Q, Abdool Karim S, Frohlich J. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Scienc. 329:1168-1174. http://dx.doi.org/10.1126/ science.1193748.
2. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT, TDF2 Study Group. 2012. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367:423-434. http://dx.doi.org/10.1056/NEJMoa1110711.
3. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C. 2012. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367:399-410. http://dx.doi.org/10.1056/NEJMoa1108524.
4. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D, FEM-PrEP Study Group. 2012. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367:411-422. http://dx.doi.org/10.1056/ NEJMoa1202614.
5. Microbicide Trials Network. 2013. VOICE fact sheet-understanding the results of VOICE. MTN, Pittsburgh, PA.
6. Akil A, Parniak MA, Dezzuitti CS, Moncla BJ, Cost MR, Li M, Rohan LC. 2011. Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv. Transl. Res. 1:209-222. http://dx.doi.org/10.1007/s13346-011-0022-6.
7. Ham AS, Rohan LC, Boczar A, Yang L, Buckheit W K, Buckheit RW. 2012. Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection. Pharm. Res. 29:1897-1907. http://dx.doi.org/10.1007/s11095-012- 0715-7.
8. Ball C, Krogstad E, Chaowanachan T, Woodrow KA. 2012. Drugeluting fibers for HIV-1 inhibition and contraception. PLoS On. 7:e49792. http://dx.doi.org/10. 1371/journal.pone.0049792.
9. Huang C, Soenen SJ, van Gulck E, Vanham G, Rejman J, Van Calenbergh S, Vervaet C, Coenye T, Verstraelen H, Temmerman M, Demeester J, De Smedt SC. 2012. Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery. Biomaterial. 33:962-969. http://dx.doi.org/10.1016/j. biomaterials.2011.10.004.
10. Emmelkamp JM, Rockstroh JK. 2008. Maraviroc, risks and benefits: a review of the clinical literature. Expert Opin. Drug Saf. 7:559-569. http://dx.doi.org/10.1517/14740338.7.5.559.
11. Malcolm RK, Forbes CJ, Geer L, Veazey RS, Goldman L, Johan Klasse P, Moore JP. 2013. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J. Antimicrob. Chemother. 68:678-683. http://dx.doi.org/10.1093/jac/dks422.
12. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. 2005. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732. http://dx.doi.org/10.1128/AAC.49.11.4721-4732. 2005.
13. Roche M, Jakobsen MR, Ellett A, Salimiseyedabad H, Jubb B, Westby M, Lee B, Lewin SR, Churchill MJ, Gorry PR. 2011. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirolog. 8:89. http://dx.doi.org/10.1186/1742-4690-8-89.
14. Malcolm RK, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJ, Doyle LA, Rasmussen KK, Goldman L, Ketas TJ, Moore JP. 2012. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob. Agents Chemother. 56:2251-2258. http://dx.doi.org/10.1128/AAC.05810-11.
15. Fetherston SM, Boyd P, McCoy CF, McBride MC, Edwards K-L, Ampofo S, Malcolm RK. 2012. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. Eur. J. Pharm. Sci. 48:406-415. http://dx.doi.org/10.1016/j.ejps.2012.12.002.
16. Forbes CJ, Lowry D, Geer L, Veazey RS, Shattock RJ, Klasse PJ, Mitchnick M, Goldman L, Doyle LA, Muldoon BCO, Woolfson AD, Moore JP, Malcolm RK. 2011. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J. Control. Releas. 156:161-169. http://dx.doi.org/10.1016/j.jconrel.2011.08.006.
17. Veazey RS, Ketas TJ, Dufour J, Moroney Rasmussen T, Green LC, Klasse PJ, Moore JP. 2010. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J. Infect. Dis. 202:739-744. http://dx.doi.org/10.1086/655661.
18. Yalkowsky SH. 1981. Techniques of solubilization of drugs. Marcel Dekker, Inc., New York, NY.
19. Leuner C. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50:47-60. http://dx.doi.org/10.1016/S0939- 6411(00)00076-X.
20. Yu D-G, Zhu L-M, Branford-White CJ, Yang J-H, Wang X, Li Y, Qian W. 2011. Solid dispersions in the form of electrospun core-sheath nanofibers. Int. J. Nanomedicin. 6:3271-3280. http://dx.doi.org/10.2147/IJN.S27468.
21. Frank KJ, Westedt U, Rosenblatt KM, Hölig P, Rosenberg J, Mägerlein M, Fricker G, Brandl M. 2012. The amorphous solid dispersion of the poorly soluble ABT-102 forms nano/microparticulate structures in aqueous medium: impact on solubility. Int. J. Nanomedicin. 7:5757-5768. http://dx.doi.org/10.2147/IJN.S36571.
22. Dahlberg C, Dvinskikh SV, Schuleit M, Furó I. 2011. Polymer swelling, drug mobilization and drug recrystallization in hydrating solid dispersion tablets studied by multinuclear NMR microimaging and spectroscopy. Mol. Pharmaceutic. 8:1247-1256. http://dx.doi.org/10.1021/mp200051e.
23. Notari S, Tommasi C, Nicastri E, Bellagamba R, Tempestilli M, Pucillo LP, Narciso P, Ascenzi P. 2009. Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV. IUBMB Lif. 61:470-475. http://dx.doi.org/10.1002/iub.181.
24. Blaine RL. 2002. Thermal applications note TN048, TA Instruments, New Castle, DE.
25. Chaowanachan T, Krogstad E, Ball C, Woodrow KA. 2013. Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS On. 8:e61416. http://dx.doi.org/10.1371/journal.pone.0061416.
26. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905. http://dx.doi.org/10.1128/AAC.46.6.1896-1905.2002.
27. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864.
28. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367. http://dx.doi.org/10.1128/JVI.74. 18.8358-8367.2000.
29. Takeuchi Y, McClure MO, Pizzato M. 2008. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 82:12585-12588. http://dx.doi.org/10. 1128/JVI.01726-08.
30. Barnhart K, Pretorius E, Timbers K, Shera D. 2004. In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraceptio. 70:498-505. http://dx.doi.org/10.1016/j. contraception.2004.06.013.
31. Nel AM, Mitchnick LB, Risha P, Muungo LTM, Norick PM. 2011. Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women. J. Womens Healt. 20:1207-1214. http://dx.doi.org/10.1089/jwh.2010.2476.
32. Johnson TJ, Gupta KM, Fabian J, Albright TH, Kiser PF. 2010. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur. J. Pharm. Sci. 39:203-212. http://dx.doi.org/10.1016/j.ejps.2009.11.007.
33. Wypych G. 2013. Handbook of plasticizers. William Andrew, Norwich, NY.
34. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiègne-Traoré V, Uaheowitchai C, Karim SSA, Mâsse B, Perriëns J, Laga M, COL-1492 Study Group. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lance. 360:971-977. http://dx.doi.org/10.1016/S0140-6736(02)11079-8.
35. D'Cruz OJ, Samuel P, Uckun FM. 2005. Conceival, a novel noncontraceptive vaginal vehicle for lipophilic microbicides. AAPS PharmSciTec. 6:E56-E64. http://dx.doi.org/10.1208/pt060111.
36. Schlievert PM, Strandberg KL, Brosnahan AJ, Peterson ML, Pambuccian SE, Nephew KR, Brunner KG, Schultz-Darken NJ, Haase AT. 2008. Glycerol monolaurate does not alter rhesus macaque (Macaca mulatta) vaginal lactobacilli and is safe for chronic use. Antimicrob. Agents Chemother. 52:4448-4454. http://dx.doi.org/10.1128/AAC.00989-08.
37. Moench T, Mumper R, Hoen T, Sun M, Cone R. 2010. Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse. BMC Infect. Dis. 10:331. http://dx.doi.org/10.1186/1471-2334-10-331.
38. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. 1983. Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharmaceutic. 15:25-35. http://dx.doi.org/10.1016/0378-5173(83)90064-9.
39. Blakney AK, Ball C, Krogstad EA, Woodrow KA. 2013. Electrospun fibers for vaginal anti-HIV drug delivery. Antiviral Res. 100:S9-S16. http://dx.doi.org/ 10.1016/j.antiviral.2013.09.022.
40. Massud I, Aung W, Martin A, Bachman S, Mitchell J, Aubert R, Tsegaye TS, Kersh E, Pau CP, Heneine W, Garcia-Lerma JG. 2013. Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. J. Virol. 87:8952-8961. http://dx.doi.org/10.1128/JVI.01204-13.
41. Nagy ZK, Wagner I, Suhajda Á, Tobak T, Harasztos AH, Vigh T, Sóti PL, Pataki H, Molnár K, Marosi G. 2014. Nanofibrous solid dosage form of living bacteria prepared by electrospinning. Express Polym. Lett. 8:352-361. http://dx.doi.org/10.3144/expresspolymlett.2014.39.